| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Argireline (Acetyl hexapeptide-3), a synthetic cosmetic, is a skin-permeable, and antiwrinkle peptide composed of 6-amino acids and used for preventing the formation of skin lines and wrinkles, inhibiting neurotransmitter release at the neuromuscular junction. It is a peptide which is a fragment of SNAP-25, a substrate of botulinum toxin. Acetyl hexapeptide-8 is marketed as Argireline by the Barcelona-based research laboratory Lipotec.
| ln Vitro |
The anti-proliferative action of hexapeptide solutions varies in dose and was seen after 48 hours of incubation with human embryonic kidney (HEK-293; IC50: 34.862 μM) and neuroblastoma IMR-32 (IC50: 68.458 μM) cells. On these cells, hexapeptide solutions at various concentrations that were treated with HSF demonstrated a dose-dependent anti-proliferative impact. Cell growth is unaffected by low hexapeptide concentrations [2].
|
|---|---|
| ln Vivo |
For six weeks, hexapeptide was administered twice a day to elderly mice. The skin tissue of elderly mice showed an improvement in histological structure; type I and type III collagen fiber counts rose and fell, respectively. Hexapeptides have the ability to regenerate aging skin by enhancing the structure of skin tissue [3].
|
| References |
[1]. Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-10.
[2]. Grosicki M, et al. The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochim Pol. 2014;61(1):29-32. [3]. Wang Y, et al. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013 Aug;15(4):237-41. |
| Molecular Formula |
C35H62N14O11S
|
|---|---|
| Molecular Weight |
887.028
|
| Exact Mass |
888.423
|
| CAS # |
616204-22-9
|
| Related CAS # |
Argireline acetate;2484708-86-1
|
| PubChem CID |
11228338
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.661
|
| LogP |
-6.67
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
61
|
| Complexity |
1610
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)N([H])C([C@]([H])(C([H])([H])C([H])([H])C(=O)O[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C(=O)O[H])N([H])C(C([H])([H])[H])=O)=O)=O
|
| InChi Key |
AJLNZWYOJAWBCR-OOPVGHQCSA-N
|
| InChi Code |
InChI=1S/C35H62N14O11S/c1-18(20(45-19(2)50)9-12-27(52)53)44-23(10-13-28(54)55)31(58)49-25(14-17-61-3)33(60)48-24(8-11-26(36)51)32(59)47-22(7-5-16-43-35(40)41)30(57)46-21(29(37)56)6-4-15-42-34(38)39/h20-25,44H,1,4-17H2,2-3H3,(H2,36,51)(H2,37,56)(H,45,50)(H,46,57)(H,47,59)(H,48,60)(H,49,58)(H,52,53)(H,54,55)(H4,38,39,42)(H4,40,41,43)/t20-,21-,22-,23-,24-,25-/m0/s1
|
| Chemical Name |
(4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
|
| Synonyms |
Acetyl Hexapeptide-3 Acetyl Hexapeptide-8 Acetyl-glu-glu-met-gln-arg-arg-amide Argireline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~112.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (56.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1274 mL | 5.6368 mL | 11.2736 mL | |
| 5 mM | 0.2255 mL | 1.1274 mL | 2.2547 mL | |
| 10 mM | 0.1127 mL | 0.5637 mL | 1.1274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA